Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com 4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com 4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com 4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com 4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com 4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com 4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 5 years ago
Hatteras Launches New Fund With $94M for Life Science Investments
@xconomy.com 5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com 5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com 5 years ago
JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston
@xconomy.com 5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com 5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com 5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com 5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com 5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com 5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com 5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com 5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com 5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com 5 years ago
TX Roundup: TMC’s BioBridge to the UK, New Execs at Fannin & TechFW
@xconomy.com 5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 5 years ago
CPRIT Grants, TMC & Baird, Shipt & Drive.ai Expand, & More TX Tech
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com 5 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing
@xconomy.com 5 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs